SCHEMBL95384

SCHEMBL95384

[CH2]c1ccc(C(=O)N2CCC(OC)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
LMNA P02545 2/20 0.52
L3MBTL3 Q96JM7 4/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
HRH3 Q9Y5N1 2/20 0.51
PARP1 P09874 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
ACHE P22303 1/20 0.47
MBTD1 Q05BQ5 1/20 0.47
TP53BP1 Q12888 1/20 0.47
L3MBTL4 Q8NA19 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PRMT5 O14744 1/20 0.47
TSHR P16473 1/20 0.47
GRM3 Q14832 1/20 0.47
ALDH1A1 P00352 1/20 0.47
IDO1 P14902 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10196662 0.86 KMT2A (0.65) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL28355752 0.86 HPGD (0.56) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL31003116 0.86 HSD11B1 (0.57) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL305207 0.85 L3MBTL3 (0.49) LMNAL3MBTL3POLBGAAKMT2A
SCHEMBL19915895 0.84 MGLL (0.56) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL28355937 0.84 EPHX1 (0.54) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL27748883 0.84 ACHE (0.68) HPGDLMNAL3MBTL3GAAKMT2A
SCHEMBL1196861 0.82 HPGD (0.54) HPGDLMNAL3MBTL3HRH3KMT2A
SCHEMBL25442209 0.82 KMT2A (0.63) HPGDLMNAL3MBTL3POLBGAA
SCHEMBL20645608 0.82 HPGD (0.50) HPGDLMNAL3MBTL3POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB HPGD 2146/4885LMNA 3740/4885L3MBTL3 1998/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 HPGD 2322/4885LMNA 4860/4885L3MBTL3 889/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 HPGD 2322/4885LMNA 4860/4885L3MBTL3 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.